We have updated our Terms & Conditions. To continue, please confirm that you have read and accept these:

You have to agree to pocketmags.com's Terms & Conditions to proceed

This website use cookies and similar technologies to improve the site and to provide customised content and advertising. By using this site, you agree to this use. To learn more, including how to change your cookie settings, please view our Cookie Policy

RESISTANCE ISN’T FUTILE

BOB FERGUSON was ready. It was the end of January, and the Washington state attorney general had been concerned that President Donald Trump would soon issue a sweeping executive order targeting immigration. A bespectacled former chess champion, Ferguson had been plotting for weeks with various immigrant rights groups in the state about how to combat Trump’s i rst move. Then, on the last Friday in January, the White House issued its now infamous executive order targeting immigration from seven predominantly Muslim countries.

Ferguson was home that weekend but went into his oi ce to work on an appeal. His solicitor general, Noah Purcell, a former U.S. Supreme Court clerk, guzzled cof ee from a full-sized Starbucks box in his office, as opposed to the chain’s ubiquitous white cup. Within a day, they had lined up two of the state’s most prominent employers, Amazon and Expedia, to sign on, and soon they had persuaded a federal judge in Seattle to put the Trump ban on hold nationwide. Just before that ruling, Ferguson told Newsweek, “I’m going to keep going where the law takes me.”

About Newsweek International

THE WAR ON ALZHEIMER'S
This aggressive attempt to prevent Alzheimer’s rather than treating it is the most exciting new development in decades, as well as a radical departure for researchers and the pharmaceutical industry. Traditionally, drug companies have tested their therapies on patients who already have memory loss, trouble thinking and other signs of dementia. It’s been a losing tactic: More than ninety nine percent of all Alzheimer’s drugs have failed tests in the clinic, and the few that have made it to the market only ameliorate some symptoms. No single medicine has been shown to slow the relentless progression of the disease. However this new approach, even partial success an appreciable slowing of brain degeneration could have a big impact, says Dr. Reisa Sperling, a neurologist who directs the Center for Alzheimer’s Researc.